Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 4/20 | 0.37 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.37 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.34 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | LAP3 | P28838 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5537099 | 1.00 | ANPEP (0.37) | ANPEPERAP2GABBR2GABBR1GABRR1 | |
| SCHEMBL6056274 | 1.00 | ANPEP (0.37) | ANPEPERAP2GABBR2GABBR1GABRR1 | |
| SCHEMBL7176498 | 0.79 | ANPEP (0.33) | ANPEPERAP2GABBR2GABBR1 | |
| SCHEMBL5529429 | 0.79 | ANPEP (0.33) | ANPEPERAP2GABBR2GABBR1 | |
| SCHEMBL7176500 | 0.79 | ANPEP (0.33) | ANPEPERAP2GABBR2GABBR1 | |
| SCHEMBL5528741 | 0.77 | ALDH1A1 (0.34) | ANPEPERAP2ALDH1A1 | |
| SCHEMBL5394771 | 0.75 | TP53 (0.45) | ANPEPERAP2GABBR2GABBR1ALDH1A1 | |
| SCHEMBL5386055 | 0.74 | ANPEP (0.35) | ANPEPERAP2GABBR2GABBR1GABRR1 | |
| SCHEMBL5388081 | 0.73 | TP53 (0.48) | ANPEPERAP2ALDH1A1 | |
| SCHEMBL5394744 | 0.73 | TP53 (0.48) | ANPEPERAP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675582-A1 | COMBINATION COMPRISING AN ALPHA-2-DELTA LIGAND AND AN SSRI AND/OR SNRI FOR TREATMENT OF DEPRESSION AND ANXIETY DISORDERS | Warner-Lambert Company LLC (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005025563-A1 | COMBINATION COMPRISING AN ALPHA-2-DELTA LIGAND AND AN SSRI AND/OR SNRI FOR TREATMENT OF DEPRESSION AND ANXIETY DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-24 | — | — | WO | disclosed |
| EP-1515709-A2 | USE OF AN ALPHA2DELTA LIGAND SUCH AS GABAPENTIN OR PREGABALIN FOR TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | Warner-Lambert Company LLC (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-1480639-A1 | COMBINATIONS OF AN ALPHA-2-DELTA LIGAND WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | Warner-Lambert Company LLC (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004002462-A2 | USE OF AN ALPHA2DELTA LIGAND SUCH AS GABAPENTIN OR PREGABALIN FOR TREATING TTENTION DEFICIT HYPERACTIVITY DISORDER | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-08 | — | — | WO | disclosed |
| WO-2003070237-A1 | COMBINATIONS OF AN ALPHA-2-DELTA LIGAND WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-28 | — | — | WO | disclosed |